Leerink analyst Mani Foroohar raised the firm’s price target on Regenxbio (RGNX) to $38 from $34 and keeps an Outperform rating on the shares after the company announced functional data from RGX-202 in Duchenne muscular dystrophy, or DMD, alongside expansion of the Phase 1/2 AFFINITY DUCHENNE trial into a single-arm pivotal trial. Following the data and trial news, the firm increased its view of the RGX-202 odds of success to 50% from 30%, the analyst tells investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz
- Regenxbio initiates pivotal phase of Affinity Duchenne trial of RGX-202
- Regenxbio assumed with an Overweight at Morgan Stanley
- Regenxbio price target raised to $40 from $39 at H.C. Wainwright
- RegenXBio Reports Progress Amid Revenue Decline